UNSPSC 51141520: Mephobarbital or methylphenobarbital

This classification denotes a barbiturate with the molecular formula C13H14N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5NC67NU76B, chemically known as 2,4,6(1h,3h,5h)-pyrimidinetrione, 5-ethyl-1-methyl-5-phenyl- but generally known as mephobarbital, which bears US NIH Compound Identifier 8271. European Medicines Agency schedules Mephobarbital in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08871MIG. The term MEPHOBARBITAL is an International Non-Proprietary Name.

World Health Organization schedules mephobarbital in its Anatomical Therapeutic Chemical (ATC) Classification. Mephobarbital or methylphenobarbital bears US NLM identifiers UMLS ID C0025382 and NCI Concept Code C76528. SMILES: O=C1N(C(=O)NC(=O)C1(CC)C1CCCCC1)C.

UNSPSC 51141520 Mephobarbital or methylphenobarbital is a Commodity code that appears to map poorly to actual state and local pharmaceutical procurement activity. The three recent opportunities tagged under this code—a naloxone and drug deactivation systems purchase from Seminole County, Florida; a direct-to-manufacturer prescription RFI from the Texas Health and Human Services Commission; and a multistate generic pharmaceuticals and OTC products RFP administered by the Minnesota Department of Administration—involve controlled substances, prescription fulfillment infrastructure, and commodity generic pharmaceuticals respectively, but do not align with the code's nominal scope of a specific barbiturate. State and local governments are clearly active in pharmaceutical procurement across multiple categories and mechanisms, but the code shows no relevant recent activity for the product it nominally describes.

The issuing bodies span county health departments, state HHS agencies, and cooperative purchasing consortia including multistate alliances. Geographic activity appears concentrated in Florida, Texas, and Minnesota based on recent postings, though cooperative purchasing vehicles like MMCAP extend reach across multiple states. The Seminole County solicitation (IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries; the Texas HHS RFI (HHS0017013, posted April 3, 2026) gathered market intelligence on direct-to-manufacturer pharmacy models; and the MMCAP RFP (S1070000015802, due March 26, 2026) established standing contracts for generic pharmaceuticals across authorized wholesalers. The code does not show current market activity for mephobarbital or methylphenobarbital specifically, making it an inactive or misaligned category for procurement tracking purposes.